MOUNTAIN VIEW, Calif., June 1, 2011 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM) announced the closing of its underwritten public offering of 6,325,000 shares of its common stock at $12.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 825,000 additional shares at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were offered by Complete Genomics.
Jefferies & Company, Inc. and UBS Investment Bank acted as joint book-running managers, with Baird and Cowen and Company acting as co-managers for the offering.
A registration statement relating to these securities has been filed with, and declared effective by, the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
This offering was made only by means of a prospectus. Copies of the prospectus for this offering may be obtained from the prospectus department of Jefferies & Company, Inc. at 520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, or via telephone at (877) 547-6340, or from the prospectus department of UBS Investment Bank at 299 Park Avenue, New York, NY 10171, Attention: Prospectus Department, or via telephone at (888) 827-7275.
About Complete Genomics
Complete Genomics is a complete human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines our proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this innovative, end-to-end, outsourced solution as CGA™ Service, and provide customers with data that is immediately ready to be used for genome-based research.
CONTACT: Complete Genomics, Inc. Scott Sandler Investor Relations (650) 943-2788 ssandler@completegenomics.com
